- Home
- CNOB vs NVAX Comparison
CNOB vs NVAX Comparison
Compare CNOB & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNOB
- NVAX
- Stock Information
- Founded
- CNOB 1982
- NVAX 1987
- Country
- CNOB United States
- NVAX United States
- Employees
- CNOB N/A
- NVAX N/A
- Industry
- CNOB Major Banks
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CNOB Finance
- NVAX Health Care
- Exchange
- CNOB Nasdaq
- NVAX Nasdaq
- Market Cap
- CNOB 1.2B
- NVAX 1.3B
- IPO Year
- CNOB 1996
- NVAX 1995
- Fundamental
- Price
- CNOB $25.48
- NVAX $7.84
- Analyst Decision
- CNOB Buy
- NVAX Hold
- Analyst Count
- CNOB 1
- NVAX 6
- Target Price
- CNOB $31.00
- NVAX $15.00
- AVG Volume (30 Days)
- CNOB 325.9K
- NVAX 8.6M
- Earning Date
- CNOB 07-29-2025
- NVAX 08-06-2025
- Dividend Yield
- CNOB 2.83%
- NVAX N/A
- EPS Growth
- CNOB N/A
- NVAX N/A
- EPS
- CNOB 0.80
- NVAX 2.54
- Revenue
- CNOB $241,854,000.00
- NVAX $1,078,718,000.00
- Revenue This Year
- CNOB $46.52
- NVAX $52.02
- Revenue Next Year
- CNOB $29.92
- NVAX N/A
- P/E Ratio
- CNOB $31.93
- NVAX $3.08
- Revenue Growth
- CNOB N/A
- NVAX 9.22
- 52 Week Low
- CNOB $20.61
- NVAX $5.01
- 52 Week High
- CNOB $29.31
- NVAX $15.22
- Technical
- Relative Strength Index (RSI)
- CNOB 64.74
- NVAX 48.26
- Support Level
- CNOB $24.04
- NVAX $7.57
- Resistance Level
- CNOB $24.40
- NVAX $10.64
- Average True Range (ATR)
- CNOB 0.58
- NVAX 0.72
- MACD
- CNOB 0.19
- NVAX -0.07
- Stochastic Oscillator
- CNOB 89.86
- NVAX 29.47
About CNOB ConnectOne Bancorp Inc.
ConnectOne Bancorp Inc is a community-based, full-service New Jersey-chartered commercial bank. Substantially all loans are secured with various types of collateral, including business assets, consumer assets and commercial/residential real estate. Each borrower's ability to repay its loans is dependent on the conversion of assets, cash flows generated from the borrowers' business, real estate rental and consumer wages.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.